Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Risk and Volatility
Silexion Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Silexion Therapeutics and Titan Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silexion Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Titan Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Silexion Therapeutics and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silexion Therapeutics | N/A | N/A | -249.43% |
| Titan Pharmaceuticals | N/A | -118.01% | -103.79% |
Institutional & Insider Ownership
10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Silexion Therapeutics and Titan Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silexion Therapeutics | N/A | N/A | $260,000.00 | N/A | N/A |
| Titan Pharmaceuticals | $180,000.00 | 19.45 | -$5.57 million | ($5.21) | -0.74 |
Silexion Therapeutics has higher earnings, but lower revenue than Titan Pharmaceuticals.
Summary
Silexion Therapeutics beats Titan Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
